International Clinical Trial: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (NCT07193511) titled 'Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Avenzo Therapeutics, Inc.

Condition: Solid Tumor Cancer Locally Advanced Metastatic Solid Tumors Urothelial Cancer

Intervention: Drug: AVZO-103

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 2025

Target Sample Size: 3...